



(51) International Patent Classification:

C07D 213/74 (2006.01) A61K 31/337 (2006.01)
 C07D 239/42 (2006.01) A61K 31/4402 (2006.01)
 C07D 295/18 (2006.01) A61K 31/505 (2006.01)
 C07D 401/12 (2006.01) A61P 11/00 (2006.01)
 C07D 487/10 (2006.01) A61P 11/06 (2006.01)
 C07D 295/192 (2006.01) A61P 17/00 (2006.01)

(21) International Application Number:

PCT/EP2009/064816

(22) International Filing Date:

9 November 2009 (09.11.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/115,145 17 November 2008 (17.11.2008) US
 61/222,262 1 July 2009 (01.07.2009) US

(71) Applicant (for all designated States except US): F.

HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacher-
 strasse 124, CH-4070 Basel (CH).

(72) Inventors; and


(75) Inventors/Applicants (for US only): FIROOZNIYA, Fari-
 borz [US/US]; 9 Pierson Lane, Florham Park, New Jersey
 07932 (US). LIN, Tai-An [US/US]; 83 Mandeville Ave-
 nue, Pequannock, New Jersey 07440 (US). SO, Sung-
 Sau [US/US]; 6 Wilmington Drive, Nutley, New Jersey
 07110 (US). WANG, Baoxia [CN/CN]; 720 Cailun
 Road, Building 5, Pudong, Shanghai, 201203 (CN).
 YUN, HongYing [CN/CN]; 802 Yinghua Road, Bldg. 1,
 Apt. 202, Shanghai, 201204 (CN).

(74) Agent: HEIROTH, Ulrike; Grenzacherstrasse 124,
 CH-4070 Basel (CH).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,

[Continued on next page]

(54) Title: NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS



(57) Abstract: The invention is concerned with the compounds of formula I and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R1-R3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.





SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*